Published in Annu Rev Microbiol on January 01, 1970
Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. Proc Natl Acad Sci U S A (1971) 5.38
Cell-mediated immunity during syphilis. Br J Vener Dis (1978) 2.70
Serologically demonstrable alloantigens of mouse epidermal cells. J Exp Med (1972) 2.48
Inhibition or enhancement of immunological injury of virus-infected cells. Proc Natl Acad Sci U S A (1971) 2.45
Why is the infectious stage of syphilis prolonged? Br J Vener Dis (1974) 2.36
Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med (1972) 2.20
The presence of tumour-specific membrane antigen in the serum of rats with chemically induced sarcomata. Br J Cancer (1973) 1.83
Properties of lymphocytes which confer adoptive immunity to tuberculosis in rats. Immunology (1973) 1.79
Immunological tolerance: "forbidden clones" allowed in tetraparental mice. Proc Natl Acad Sci U S A (1971) 1.67
Effect of neuraminidase on the stimulatory capacity of cells in human mixed lymphocyte cultures. Clin Exp Immunol (1971) 1.32
Active suppression as a possible mechanism of tolerance in tetraparental mice. J Exp Med (1973) 1.25
The specificity of serum factors in lymphocyte transformation in periodontal disease. Clin Exp Immunol (1973) 1.21
The mechanism of tolerance in contact hypersensitivity to dinitrochlorobenzene in guinea-pigs. Clin Exp Immunol (1974) 1.20
Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy. Br J Cancer (1973) 1.17
Immunologic and genetic factors influencing reproduction. A review. Am J Pathol (1979) 1.12
Interspecies brain antigen detected by naturally occurring mouse anti-brain autoantibody. Proc Natl Acad Sci U S A (1975) 1.09
Immunological paralysis of mice with pneumococcal polysaccharide antigens. Bacteriol Rev (1971) 1.04
Persistent infection of the mouse with the virus of lymphocytic choriomeningitis. J Clin Pathol Suppl (R Coll Pathol) (1972) 1.04
Suppression of immunity to Mycobacterium lepraemurium infection. Infect Immun (1977) 1.04
Preparation of a "chemical vaccine" against tumor progression. Proc Natl Acad Sci U S A (1971) 1.03
Autoregulation of immune responses via idiotype network interactions. Microbiol Rev (1980) 1.01
Immune response to a syngeneic rat tumour: evolution of serum cytotoxicity and blockade. Br J Cancer (1973) 1.00
Inhibition of specific cell-mediated cytotoxicity by anti-T-cell receptor antibody. J Exp Med (1974) 0.99
Immunotherapy in patients with melanoma. Ann Surg (1973) 0.98
Demonstration of cytotoxic antibodies in rabbits bearing tumors induced by Shope fibroma virus. Infect Immun (1972) 0.93
Tumor-secific immunity to chemically induced tumors. Evidence for immunologic specificity and shared antigenicity in lymphocyte responses to soluble tumor antigens. J Exp Med (1975) 0.91
Significance of serum factors modifying cellular immune responses to growing tumours. Br J Cancer Suppl (1973) 0.91
Specific suppression of delayed hypersensitivity skin reactions to collagen in guinea-pigs after immunization with collagen and Freund's incomplete adjuvant. Immunology (1976) 0.90
Characterization of a T-lymphocyte inhibitor in the serum of tumour-bearing mice. Immunology (1976) 0.89
Cellular-versus-humoral autoimmune responses to salivary gland in Sjögren's syndrome. Clin Exp Immunol (1973) 0.87
In vitro desensitization of sensitized murine lymphocytes by a serum factor (soluble antigen?). Proc Natl Acad Sci U S A (1971) 0.86
Hydantoin immunosuppression and carcinogenesis. Clin Exp Immunol (1975) 0.80
Lymphocyte tissue culture studies on human heart transplant recipients. I. Screening recipients for serum factors which inhibit the mixed lymphocyte reaction. Ann Surg (1974) 0.79
Recovery of immune competence after tumour resection in mice: correlation with loss of suppressor elements. Br J Cancer (1978) 0.78
Histocompatibility studies in a closely bred colony of dogs. V. Mechanisms of cellular adaptation in long-term DL-A identical radiation chimeras. J Exp Med (1975) 0.78
Lymphocyte depression by cancer. Ann R Coll Surg Engl (1977) 0.77
Induction of immunological tolerance to allogeneic tissues in the canine species. Ann Surg (1972) 0.76
The effect of preadministration of Corynebacterium parvum on the protection afforded by heat-killed and acetone-killed vaccines against experimental mouse typhoid. J Hyg (Lond) (1974) 0.75
The role of immunology in the diagnosis, prognosis and treatment planning of oral cancer. Proc R Soc Med (1976) 0.75
Binding of 125I-labelled encephalitogenic basic protein to normal lymphocytes. Inhibition with multiple sclerosis serum. Clin Exp Immunol (1975) 0.75
Mixed lymphocyte reactivity against normal cells by splenic lymphocytes from tumor-bearing mice : ii. Studies of autoimmune-like activity in completely syngeneic and semisyngeneic systems. J Exp Med (1974) 0.75
Alternatives to animal experiments in medical research. Br Med J (1974) 0.75
Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. Proc Natl Acad Sci U S A (1971) 5.38
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 4.34
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
Cellular immunity against tumor antigens. Adv Cancer Res (1969) 3.70
Abrogation of cellular immunity to antigenically foreign mouse embryonic cells by a serum factor. Nature (1969) 3.20
Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms. Int J Cancer (1971) 3.06
Demonstration of cell-mediated immunity to human neoplasms of various histological types. Int J Cancer (1971) 2.88
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A (1999) 2.87
Studies on cellular immunity and its serum mediated inhibition in Moloney-virus-induced mouse sarcomas. Int J Cancer (1969) 2.80
Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol (1974) 2.68
Cellular and humoral immunity to different types of human neoplasms. Nature (1968) 2.40
Cell surface antigens of human melanoma identified by monoclonal antibody. Proc Natl Acad Sci U S A (1979) 2.40
Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens. Proc Natl Acad Sci U S A (1969) 2.28
Phosphorylation of synthetic peptides by a tyrosine protein kinase from the particulate fraction of a lymphoma cell line. Proc Natl Acad Sci U S A (1982) 2.25
Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. Proc Natl Acad Sci U S A (1980) 2.14
Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Natl Acad Sci U S A (1968) 2.12
Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med (1994) 1.93
Elution of "blocking factors" from human tumors, capable of abrogating tumor-cell destruction by specifically immune lymphocytes. Int J Cancer (1972) 1.76
The x-ray structure of an anti-tumour antibody in complex with antigen. Nat Struct Biol (1995) 1.76
Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res (1986) 1.75
In vitro studies of immune reactions against autochthonous and syngeneic mouse tumors induced by methylcholanthrene and plastic discs. Int J Cancer (1968) 1.73
Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci U S A (1981) 1.70
Immunological tolerance: "forbidden clones" allowed in tetraparental mice. Proc Natl Acad Sci U S A (1971) 1.67
Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci U S A (1987) 1.61
Costimulation of T cells for tumor immunity. Immunol Today (1993) 1.57
Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res (1990) 1.57
Cellular immunity and its serum-mediated inhibition in Shope-virus-induced rabbit papillomas. Int J Cancer (1969) 1.56
Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science (1993) 1.47
Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci U S A (1991) 1.47
Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence. Proc Natl Acad Sci U S A (1986) 1.46
Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population. J Exp Med (1978) 1.46
Human melanoma-associated antigen p97 is structurally and functionally related to transferrin. Nature (1982) 1.45
Neonatally induced allograft tolerance may be mediated by serum-borne factors. Nature (1971) 1.43
Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest (1983) 1.42
Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci U S A (1988) 1.41
Antibody response of mice to chemically induced tumors. Proc Natl Acad Sci U S A (1978) 1.41
Cell-mediated immunity against antigens common to human colonic carcinomas and fetal gut epithelium. Int J Cancer (1970) 1.40
Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol (1994) 1.39
Protein antigens of normal and malignant human cells identified by immunoprecipitation with monoclonal antibodies. J Biol Chem (1980) 1.37
A microassay for antibody binding to tumor cell surface antigens using 125I-labelled protein a from Staphylococcus aureus. J Immunol Methods (1977) 1.36
Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep (1984) 1.35
Granule membrane protein 140 (GMP140) binds to carcinomas and carcinoma-derived cell lines. Proc Natl Acad Sci U S A (1992) 1.32
Sequential studies on cell-mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma. Int J Cancer (1973) 1.30
Detection of a human melanoma-associated antigen, p97, in histological sections of primary human melanomas. Int J Cancer (1982) 1.29
Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies. J Immunol (1981) 1.27
Serum factors in tumor-free patients cancelling the blocking of cell-mediated tumor immunity. Int J Cancer (1971) 1.27
Immunological studies on urinary bladder tumors of rats and mice. Science (1972) 1.25
Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2. J Biol Chem (1982) 1.25
Imaging of melanoma with L-131-labeled monoclonal antibodies. J Nucl Med (1983) 1.24
Demonstration of H-2 isoantigens and polyoma specific tumor antigens by measuring colony formation in vitro. Exp Cell Res (1965) 1.23
Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol (1987) 1.23
Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc Natl Acad Sci U S A (1985) 1.23
Some recent studies on cellular immunity to human melanomas. Fed Proc (1973) 1.22
Allogeneic inhibition of tumour cells by in vitro contact with cells containing foreign H-2 antigens. Nature (1965) 1.22
Indirect 125I-labeled protein A assay for monoclonal antibodies to cell surface antigens. J Immunol Methods (1979) 1.20
Studies on cellular immunity to human neuroblastoma cells. Int J Cancer (1970) 1.19